BioXcel ends commercial support for Igalmi as focus turns to neuro candidate
BioXcel Therapeutics (BTAI) stock gains as company shifts focus from commercial support for FDA-approved drug, Igalmi to lead ...
Daily16h
intraoperative low‑dose ketamine and dexmedetomidine fail to improve bowel recovery after complex GI malignancy surgeries: Study
Patients undergoing complex gastrointestinal malignancy surgeries experience various challenges such as immune system ...
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia ...
Daily3d
Dexmedetomidine and ketamine infusions improve patient tolerance during noninvasive ventilation after chest trauma, Study finds
Research on using sedation to improve patient tolerance to noninvasive ventilation (NIV) after traumatic chest injuries is ...
Science Daily14d
Anesthesia overrides carbon dioxide in regulating cerebrospinal fluid flow
A study on the effects of commonly used anaesthetic and sedative drugs on cerebrospinal fluid flow and volume has uncovered findings regarding their impact on the brain's vital glymphatic system.
Pharmaceutical Technology28d
BioXcel Therapeutics gets grant for methods for treating agitation with dexmedetomidine without sedation
The granted patent US11998529B2 outlines a method for treating agitation in human subjects using an oromucosal formulation of dexmedetomidine. The treatment protocol involves administering an initial ...
Frontiers29d
Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database
Reporting odds ratio (ROR), the proportional reporting ratio (PRR), and the Bayesian confidence propagation neural network (BCPNN) were employed to detect and assess adverse events associated with ...